Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund decreased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 59.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 274,800 shares of the company’s stock after selling 405,200 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Teva Pharmaceutical Industries were worth $3,877,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CANADA LIFE ASSURANCE Co raised its stake in Teva Pharmaceutical Industries by 25.9% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 480,299 shares of the company’s stock worth $6,778,000 after acquiring an additional 98,710 shares during the last quarter. UniSuper Management Pty Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 109.2% in the first quarter. UniSuper Management Pty Ltd now owns 15,900 shares of the company’s stock valued at $224,000 after purchasing an additional 8,300 shares during the period. O Shaughnessy Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter worth about $166,000. Acadian Asset Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 180.9% during the first quarter. Acadian Asset Management LLC now owns 589,585 shares of the company’s stock worth $8,315,000 after purchasing an additional 379,677 shares during the period. Finally, Vanguard Group Inc. boosted its position in Teva Pharmaceutical Industries by 3.5% in the first quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TEVA shares. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Barclays raised their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, June 5th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.56.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Vikki L. Conway sold 15,219 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 549,719 shares of company stock valued at $9,353,736. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $16.81 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The stock has a 50 day simple moving average of $16.75 and a 200-day simple moving average of $14.48.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). The company had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.